Piper Jaffray analyst Joshua Schimmer weighed in today with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the company announced that data from its ongoing Phase …
bluebird bio Inc (NASDAQ:BLUE) keeps hitting its marks. The first Sickle Cell patient treated with LengiGlobin, bluebird’s one-time gene therapy product, is producing healthy red …
bluebird bio Inc (NASDAQ:BLUE) ares increased 3.8% to $179 in pre-market trading after the company announced it will be presenting data on LentiGlobin, a …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, …
In a research report published Tuesday, J.P.
bluebird bio Inc (NASDAQ:BLUE) , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based …
Quick SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) forecast update: Back on November 10th 2014 we predicted a spring 2015 high of 2181 …
On April 29, Joshua Schimmer of Piper Jaffray released a report highlighting several biopharmaceutical companies tackling Sickle Cell Disease, or SCD. The hereditary blood disorder …
Following the annual J.P.
One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …
